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S pontaneous portosystemic shunt (PSS) from portal hypertension is associated with portal vein (PV) stasis and chronic hepatic encephalopathy (HE). 1 Embolization of PSS is effective in select cases of refractory HE, but is relatively contraindicated in patients with portal vein thrombosis (PVT) ( Table 1) . [2] [3] [4] [5] [6] [7] [8] This procedure redirects significant blood flow back through the PV and has been reported to improve liver function. 5, 9 We present a case of a new PVT in a cirrhosis patient with refractory HE thought secondary to PSS. This was treated sequentially with 6 months anticoagulation to achieve PV patency, followed by partial coil embolization of a large PSS. One year later, imaging revealed a 54% increase in liver volume.
Case Report
A 46-year-old man with cirrhosis secondary to primary sclerosing cholangitis followed for 8 years had been noted to decline over 1 year prior to presenting with acute onset abdominal pain and worsening HE. Computed tomography (CT) revealed an atrophic liver with a new PVT in a diminutive PV and increased size of previously identified splenorenal shunt (SRS). Endoscopy revealed no esophageal varices and small, low-risk gastric fundal varices. The Model for Endstage Liver Disease (MELD) score prior to warfarin therapy was 12 (Table 2) . Anticoagulation was started with warfarin to a goal international normalized ratio (INR) of 2-3. He continued to require hospitalization for HE despite adherence to medical therapy. Follow-up imaging 4 months after starting warfarin revealed interval partial recanalization of the main diminutive PV with a residual large SRS and atrophic liver. The patient continued to struggle with severe HE and therapeutic shunt obliteration was pursued.
A hepatic venogram and catheterization of SRS was performed to evaluate hemodynamic response to shunt occlusion in anticipation of future embolization. This study revealed a patent main diminutive PV with sluggish velocities (peak velocity in the main PV 6.9 cm/s). The large SRS demonstrated an average flow volume of 325 mL/ min. Test balloon occlusion of the SRS resulted in an increase in main PV peak velocity to 90.1 cm/s. Next, a partial coil embolization of the SRS was performed resulting in 30% decreased flow (Fig. 1) . Concurrent PV ultrasound demonstrated conversion of hepatofugal blood prior to the procedure (25 cm/s) to hepatopetal flow (20 cm/s).
The patient did very well, with a significant reduction in fatigue and marked improvement in cognition. Biochemical indices improved (Table 2 ). Ascites and high-risk esophageal varices have not developed to date, while the platelet level has remained unchanged. A follow-up CT scan 9 months after this procedure revealed a 54% increase in liver volume (Fig. (Fig. 2) .
Discussion
This case represents successful sequential therapy of a PVT with anticoagulation to reestablish patency, 2 This study found that patients with a MELD of less than 11 responded best to therapy. Notably, patients with PVT were excluded.
Since antiquity, as recounted in the Greek myth of Prometheus, the remarkable capabilities of the liver to regenerate have fascinated mankind. 10 Moreover, surgical advancements in partial hepatic resection and living donor liver transplantation have built upon this understanding. 11 Chronic or acute ischemia from thrombosis can result in hepatocyte apoptosis and atrophy, potentially resulting in worsening liver function and progressive liver disease. 12 Recently, Villa et al. 13 showed that prevention of PVT with prophylactic enoxaparin decreased the incidence of PVT, and reduced decompensation events. Reduction in blood flow by micro and macro thrombosis and/or redirection of flow through a PSS (both present in this case) may deprive the liver of important components (growth factors and cytokines) necessary to compensate for chronic injury. Reversal of this process with anticoagulation and redirection of blood flow through the liver may offer important therapeutic benefit. Whether this case represents true hepatic regeneration is unclear, as we did not conduct functional testing and instead relied on CT-reconstructed volumetric comparison. We are limited by inherent potential inaccuracies of indirect volume measurement and did not account for volume status of the patient. However, we suspect (as evidenced by clinical and biochemical improvement in the patient) some component of hepatic regeneration occurred with the restoration of portal venous flow to the liver.
Redirection of blood flow likely served to reduce stasis and augment better perfusion by way of the diminutive PV. In this case, we believe the combination of anticoagulation and embolization simultaneously reduced HE and improved hepatic function. As this procedure can exacerbate portal hypertension, more studies are needed to delineate which particular patients may benefit the most.
